Therapeutics
Search By Attributes
Search Results
Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
---|---|---|---|---|---|---|
ABBV-916 | N3pG-Abeta mAb | Alzheimer's Disease (Phase 2) | Amyloid-Related | Immunotherapy (passive) | ||
Donanemab | N3pG-Aβ Monoclonal Antibody, LY3002813 |
Alzheimer's Disease (Phase 3) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | |
Gamunex | Intravenous Immunoglobulin, Human Albumin Combined With Flebogamma |
Alzheimer's Disease (Phase 2/3) | Grifols Biologicals Inc. | Amyloid-Related, Inflammation | Combination, Immunotherapy (passive) | Immunodeficiency, chronic inflammatory demyelinating neuropathy |
Remternetug | LY3372993, N3pG-Abeta mAb |
Alzheimer's Disease (Phase 3) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) |